Intended Audience:PCPs (nurses, PA)
Bayer TA Rationale for Educational Support:
- HF Disease Burden, with focus on HFmrEF and HFpEF (LVEF ≥40%)(highlight contemporary disease definitions, understanding of pathophysiology, etc.)
- Importance of co-morbid conditions
- Current SoC for patients with HFmrEF and HFpEF, Treatment gaps, and residual risk
- Unique properties of non-steroidal MRAs vs steroidal MRAs
- Efficacy Data
- FINEARTS-HF trial and relevant subanalyses
- FINEHEART trial
- Safety and tolerability
Intended Audience: Cardiologist, Endocrinologist, Nephrologist, Internal Medicine
Bayer TA Rationale for Educational Support:
Rationale for Educational Support:
- HFmrEF/HFpEF (LVEF ≥40%) disease burden, with focus on epidemiology, clinical outcomes, current understanding of pathophysiology
- Current SoC for patients with HFmrEF and HFpEF, real world utilization of recommended therapies, and residual risk
- Unique properties of non-steroidal MRAs vs steroidal MRAs
- Efficacy data
- FINEARTS-HF trial and relevant subanalyses
- FINEHEART trialMRS vs SMRA
- Safety and tolerability
Preferred Format:
- Enduring
- Downloadable slides
- Incorporation of social media outreach (You-Tube, FaceBook, Spotify, LinkedIn, Twitter)
- Podcast
- Live Virtual
Proposal Requirements:
The proposal must be compliant with standards and guidelines for commercial support (e.g., ACCME).
The proposal should include:
- Needs assessment
- Educational design and rationale for selection (where applicable)
- Learning Objectives
- Proposed Faculty
- Participant recruitment plan (where applicable)
- Outcomes strategy/plan
- Detailed budget (please use the template available on the website)
Provider Justification:
Copy of most recent accreditation letter and status
Process
Applications/proposals which are submitted and determined to be complete are reviewed monthly. Allow a minimum of 45 days from submission for response.
Acceptance of a Bayer educational grant indicates that you will:
- Reconcile grant funding within 60 days of completion of the educational program
- Permit a Bayer Medical Affairs representative to audit live programs
- Share activity data and outcomes metrics within 30 days of their availability
References:
Publication References
- Solomon et al. Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. NEJM. DOI: 10.1056/NEJMoa2407107
- Desai AS et al. Finerenone in Patients With a Recent Worsening Heart Failure Event: The FINEARTS-HF Trial. J Am Coll Cardiol. 2024 Sep 25:S0735-1097(24)08452-3. doi: 10.1016/j.jacc.2024.09.004. Online ahead of print.
- Vaduganathan et al. Time to Significant Benefit of Finerenone in Patients With Heart Failure. J Am Coll Cardiol. 2024 Sep 26:S0735-1097(24)08512-7. doi: 10.1016/j.jacc.2024.09.018. Online ahead of print.
- Vaduganathan M et al. Effects of the Non-Steroidal MRA Finerenone with and without Concomitant SGLT2 Inhibitor Use in Heart Failure. Circulation. 2024 Sep 28. doi: 10.1161/CIRCULATIONAHA.124.072055. Online ahead of print.
- Docherty KF et al. Efficacy and Safety of Finerenone Across the Ejection Fraction Spectrum in Heart Failure with Mildly Reduced and Preserved Ejection Fraction: a Prespecified Analysis of The FINEARTS-HF Trial. Circulation. 2024 Sep 29. doi: 10.1161/CIRCULATIONAHA.124.072011. Online ahead of print.
- Chimura M et al. Finerenone Improves Outcomes in Patients with Heart Failure with Mildly Reduced or Preserved Ejection Fraction Irrespective of Age: A Prespecified Analysis of FINEARTS-HF. Circ Heart Fail. 2024 Sep 29. doi: 10.1161/CIRCHEARTFAILURE.124.012437. Online ahead of print.
- Chang J et al. Mineralocorticoid Antagonism in Heart Failure: Established and Emerging Therapeutic Role. JACC Heart Fail. 2024 Sep 1:S2213-1779(24)00606-1. doi: 10.1016/j.jchf.2024.08.007. Online ahead of print.